Jiang T, Zhang Y, Li X, et al. - Researchers sought to determine the benefits of epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKIs) plus bevacizumab in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) and multiple brain metastases (BrMs). Among 208 patients with EGFR-mutant NSCLC and multiple BrM (number > 3, at least one of lesions was measurable), 149 patients were administered EGFR-TKIs monotherapy and 59 were administered EGFR-TKIs plus bevacizumab as a first-line setting. Outcomes revealed the achievement of significantly improved progression-free survival and overall survival for patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastasis with the administration of EGFR-TKI plus bevacizumab. The groups had acceptable and manageable adverse effects and had no unexpected serious adverse effects. Findings support a possible value of EGFR-TKIs plus bevacizumab as an alternative therapeutic option for those patients.